🇺🇸 FDA

Company profile · Sponsor

Istituto

Istituto Gentili S.r.l.

EE1E257 · EMA pharma EU
Pipeline
24
Drugs
0
Patents
0

Quick answer

Istituto (EE1E257) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EE1E257
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (24)

Search pipeline →

  1. Augmentin Fruit, 400 mg/57 mg/5 ml suukaudse suspensiooni pulber

    Istituto

    Urinary Tract Infections

    phase 3 small molecule active

    1 trial

  2. GLASDEGIB , DAUNORUBICIN , AZACITIDINE , AMSACRINE , CYTARABINE , DECITABINE , FLUDARABINE , ETOPOSIDE , GILTERITINIB, IDARUBICIN , VENETOCLAX , MITOXANTRONE , IVOSIDENIB , CYTARABINE , CLADRIBINE , GEMTUZUMAB OZOGAMICIN

    Istituto

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  3. Intrarosa 6.5 mg pessary

    Istituto

    Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).

    phase 3 small molecule active

    1 trial

  4. PLACEBO, Nicetile 500 mg polvere per soluzione orale

    Istituto

    amyotrophic lateral sclerosis

    phase 3 small molecule active

    1 trial

  5. Placebo is solution for injection (150 mg/ml) contained in vials equal to those of Canakinumab and appears identical to the Test product. Placebo is provided by Novartis pharma., Ilaris 150 mg/ml solution for injection

    Istituto

    PAPA syndrome

    phase 3 small molecule active

    1 trial

  6. Sugammadex 100 mg/ml solution for injection, Rocuronium bromide 10 mg/ml solution for injection/infusion

    Istituto

    patients scheduled to undergo elective surgical procedures with general anesthesia

    phase 3 small molecule active

    1 trial

  7. Veltassa 8.4 g powder for oral suspension, Placebo

    Istituto

    End Stage Kidney Disease on chronic dialysis therapy

    phase 3 small molecule active

    1 trial

  8. Wegovy 2.4 mg solution for injection in pre-filled pen, Rybelsus 14 mg tablets, Clopidogrel Medreg 75 mg filmom obalené tablety, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 0.5 mg solution for injection in pre-filled pen, Wegovy 1 mg solution for injection in pre-filled pen, Rybelsus 7 mg tablets, Wegovy 1.7 mg solution for injection in pre-filled pen, Acetylsalicylic acid Krka 100 mg enterotabletter, Rybelsus 3 mg tablets

    Istituto

    Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)

    phase 3 small molecule active

    1 trial

  9. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto

    PSMA PET/CT positive advanced/metastatic tumours

    phase 2 small molecule active

    1 trial

  10. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto

    Oligometastatic prostate carcinoma

    phase 2 small molecule active

    1 trial

  11. 68Ga-FAPI-46

    Istituto

    oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT

    phase 2 small molecule active

    1 trial

  12. 68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket)

    Istituto

    Solid tumors

    phase 2 other active

    1 trial

  13. AMINOHIPPURIC ACID, OMNIPAQUE 300 mg I/ml soluzione iniettabile, Felzartamab

    Istituto

    Membranous nephropathy

    phase 2 small molecule active

    1 trial

  14. Argon/Oxygen mixture, OXYGEN

    Istituto

    Cardiac arrest

    phase 2 small molecule active

    1 trial

  15. BEVACIZUMAB, DC-VACCINE_IRSTIRCCS, Lonsurf 20 mg/8.19 mg film-coated tablets, VEGZELMA 25 mg/mL concentrate for solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BEVACIZUMAB

    Istituto

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  16. BLEOPRIM 15 mg polvere per soluzione iniettabile, Carboplatino AHCL 10 mg/ml Concentrato per soluzione per infusione

    Istituto

    relapsing vulvar carcinoma already subjected to multiple treatments

    phase 2 small molecule active

    1 trial

  17. CYCLOPHOSPHAMIDE MONOHYDRATE, VINORELBINE, Tecentriq 840 mg concentrate for solution for infusion

    Istituto

    Inoperable locally advanced or metastatic TNBC patients, previously treated with anti-PD-L1/PD1- regimens

    phase 2 small molecule active

    1 trial

  18. DC-VACCINE_IRSTIRCCS, Proleukin 18 x 106 UI Polvere per soluzione iniettabile o per infusione

    Istituto

    Stage IV colorectal cancer

    phase 2 small molecule active

    1 trial

  19. DURVALUMAB, Ceralasertib

    Istituto

    Stage III NSCLC patients with loco-regional relapse > 12 months from the end of CRT +/- < 3 metastatic lesions after PACIFIC regimen or PACIFIC-like regimens (concurrent or sequential chemo-radiotherapy followed by maintenance durvalumab), regardless of PD-L1 status, but without EGFR, HER-2 or MET exon14 skipping mutations, ALK, ROS1, RET or NTRK rearrangements.

    phase 2 small molecule active

    1 trial

  20. EstroTep 500 MBq/mL, solution injectable, ELACESTRANT, EXEMESTANE, ELACESTRANT

    Istituto

    Metastatic hormone receptor-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  21. Fycompa 4 mg film-coated tablets, Fycompa 2 mg film-coated tablets

    Istituto

    White-Sutton syndrome (POGZ-Related Disorder)

    phase 2 small molecule active

    1 trial

  22. Gazyvaro 1,000 mg concentrate for solution for infusion., OMNIPAQUE 300 mg I/ml soluzione iniettabile

    Istituto

    Idiopathic Nephrotic Syndrome

    phase 2 small molecule active

    1 trial

  23. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan Baxter 50 mg Compresse rivestite

    Istituto

    Locally recurrent, inoperable, and/or metastatic inflammatory breast cancer with lymphangitic spread to the chest wall

    phase 2 small molecule active

    1 trial

  24. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CISPLATIN , CARBOPLATIN

    Istituto

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Istituto?

Istituto (EE1E257) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Istituto sponsor?

We track 24 ClinicalTrials.gov-linked programs for Istituto, including Augmentin Fruit, 400 mg/57 mg/5 ml suukaudse suspensiooni pulber and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Istituto company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.